| Literature DB >> 28638412 |
Mohamed F El-Badawy1,2, Wael M Tawakol1, Shaymaa W El-Far3, Ibrahim A Maghrabi4, Saleh A Al-Ghamdi2, Moselhy S Mansy5, Mohammed S Ashour5, Mohamed M Shohayeb2,6.
Abstract
Inappropriate use of antibiotics in clinical settings is thought to have led to the global emergence and spread of multidrug-resistant pathogens. The goal of this study was to investigate the prevalence of genes encoding aminoglycoside resistance and plasmid-mediated quinolone resistance among clinical isolates of Klebsiella pneumoniae. All K. pneumoniae isolates were phenotypically identified using API 20E and then confirmed genotypically through amplification of the specific K. pneumoniae phoE gene. All isolates were genotyped by the enterobacterial repetitive intergenic consensus polymerase chain reaction technique (ERIC-PCR). Antibiotic susceptibility testing was done by a modified Kirby-Bauer method and broth microdilution. All resistant or intermediate-resistant isolates to either gentamicin or amikacin were screened for 7 different genes encoding aminoglycoside-modifying enzymes (AMEs). In addition, all resistant or intermediate-resistant isolates to either ciprofloxacin or levofloxacin were screened for 5 genes encoding the quinolone resistance protein (Qnr), 1 gene encoding quinolone-modifying enzyme, and 3 genes encoding quinolone efflux pumps. Biotyping using API 20E revealed 13 different biotypes. Genotyping demonstrated that all isolates were related to 2 main phylogenetic groups. Susceptibility testing revealed that carbapenems and tigecycline were the most effective agents. Investigation of genes encoding AMEs revealed that acc(6')-Ib was the most prevalent, followed by acc(3')-II, aph(3')-IV, and ant(3'')-I. Examination of genes encoding Qnr proteins demonstrated that qnrB was the most prevalent, followed by qnrS, qnrD, and qnrC. It was found that 61%, 26%, and 12% of quinolone-resistant K. pneumoniae isolates harbored acc(6')-Ib-cr, oqxAB, and qebA, respectively. The current study demonstrated a high prevalence of aminoglycoside and quinolone resistance genes among clinical isolates of K. pneumoniae.Entities:
Year: 2017 PMID: 28638412 PMCID: PMC5468591 DOI: 10.1155/2017/8050432
Source DB: PubMed Journal: Int J Microbiol
Primer sets and PCR cycling conditions used for genotyping and amplification of genes encoding AMES.
| Primer | Sequence | Gene | Reference | Amplification conditions | Amplicon size (bp) |
|---|---|---|---|---|---|
| aac(3′)-II |
|
| [ |
| 877 |
|
| |||||
| aac(6′)-Ib |
|
| [ |
| 472 |
| aac(6′)-II |
|
| [ | 542 | |
|
| |||||
| ant(3′′)-I |
|
| [ |
| 787 |
|
| |||||
| aph(3′)-VI |
|
| [ |
| 780 |
| armA |
|
| [ | 846 | |
|
| |||||
| rmtB |
|
| [ |
| 769 |
|
| |||||
| phoE |
|
| [ |
| 368 |
| ERIC-1R |
| — | [ | — | |
acc: aminoglycoside acetyl transferase, ant: aminoglycoside nucleotidyl transferase, aph: aminoglycoside phosphor transferase, arm: aminoglycoside ribosomal methylase, and rmt: ribosomal methylase, phoE; phosphoporin E, ERIC, enterobacterial repetitive intergenic consensus.
Primer sets and PCR cycling conditions used for amplification of genes encoding quinolone resistance.
| Prime | Sequence | Gene | Reference | Amplification conditions | Amplicon size (bp) |
|---|---|---|---|---|---|
| QnrA |
| qnrA | [ |
| 580 |
| QnrB |
|
| [ | 264 | |
| QnrC |
|
| [ | 307 | |
|
| |||||
| QnrD |
|
| [ |
| 533 |
| QnrS |
|
| [ | 428 | |
| ACC (6′)-Ib-cr |
|
| [ | 482 | |
|
| |||||
| OqxA |
|
| [ |
| 392 |
|
| |||||
| OqxB |
|
| [ |
| 512 |
|
| |||||
| Qep |
|
| [ |
| 596 |
qnr: quinolone resistance protein, acc(6′)-Ib-cr: aminoglycoside acetyl transferase-ciprofloxacin variant, Oqx: olaquindox, and Qep: quinolone efflux pump.
Figure 1Representative DNA fingerprint pattern of K. pneumoniae clinical isolates genotyped by ERIC-PCR.
Figure 2Generated UPGMA dendrogram based on Dice similarity coefficient for clustering of K. pneumoniae isolates using ERIC-PCR as DNA fingerprinting method. KL: Klebsiella pneumoniae, PGA: phylogenetic group A, and PGB: phylogenetic group B.
Antibiotic susceptibility of K. pneumoniae clinical isolates.
| Antibiotic |
| MIC50 and MIC90 | |||
|---|---|---|---|---|---|
| Sensitive | Intermediate | Resistant | MIC50 | MIC90 | |
| Number (%) | Number (%) | Number (%) | |||
| Cefotaxime | 15 | 1 | 98 | 256 | >1024 |
| Ceftazidime | 26 | 14 | 74 | 32 | >1024 |
| Cefoperazone | 17 | 3 | 94 | 512 | >1024 |
| Cefoperazone/sulbactam | 51 | 12 | 51 | 32 | 1024 |
| Ceftriaxone | 18 | — | 96 | 256 | >1024 |
| Cefepime | 21 | 24 | 69 | 32 | 256 |
| Imipenem | 86 | 5 | 23 | ≤0.5 | 4 |
| Meropenem | 85 | 2 | 27 | ≤0.5 | 16 |
| Tetracycline | 32 | 4 | 78 | 128 | 512 |
| Tigecycline | 111 | — | 3 | ≤0.5 | ≤0.5 |
| Gentamicin | 46 | 12 | 56 | 8 | >1024 |
| Amikacin | 84 | 1 | 29 | ≤0.5 | >1024 |
| Thiamphenicol | 7 | 2 | 105 | 1024 | >1024 |
| Ciprofloxacin | 60 | 3 | 51 | 1 | 128 |
| Levofloxacin | 65 | 5 | 44 | ≤0.5 | 64 |
Figure 3Representative PCR products of detected genes encoding AMEs. Lanes: (1) ant (3′′)-I; (L) 100 bp ladder; (2) armA; (3) acc(6′)-Ib; (4) aph(3′)-VI; (5) acc(3-)-II.
Resistance pattern and genetic profile of quinolone and aminoglycoside resistant K. pneumoniae isolates.
| Isolate number | Quinolone and aminoglycoside resistance profile | Quinolone resistance genetic profile | Number of quinolone resistance genes | Aminoglycoside resistance genetic profile | Number of aminoglycoside resistance genes | Total number of detected genes |
|---|---|---|---|---|---|---|
| KLP2 | CN, AK, CIP |
| 4 |
| 2 | 6 |
| KLP3 | CN, CP, LEV |
| 3 |
| 2 | 5 |
| KLP5 | CN | NA | NA |
| 2 | 2 |
| KLP6 | CN | NA | NA |
| 2 | 5 |
| KLP13 | CN, AK, CIP, LEV |
| 3 | — | — | 3 |
| KLP14 | CN, AK, CIP, LEV |
| 1 |
| 2 | 3 |
| KLP15 | CN, AK, CIP |
| 3 |
| 5 | 8 |
| KLP19 | CN, AK, CIP, LEV |
| 3 |
| 2 | 5 |
| KLP20 | CN, AK, CIP, LEV |
| 2 |
| 2 | 4 |
| KLP23 | CN, AK, CIP, LEV |
| 4 |
| 3 | 7 |
| KLP27 | CN, CIP, LEV |
| 3 |
| 2 | 5 |
| KLP28 | CN, CIP, LEV |
| 2 |
| 3 | 5 |
| KLP29 | CN, AK, CIP |
| 2 |
| 4 | 6 |
| KLP30 | CN, AK, CIP, LEV |
| 5 |
| 4 | 9 |
| KLP33 | CN, CIP, LEV |
| 4 |
| 4 | 8 |
| KLP34 | CN |
| 1 |
| 3 | 4 |
| KLP35 | CN, CIP |
| 1 |
| 3 | 4 |
| KLP36 | CN, AK, CIP, LEV |
| 1 |
| 2 | 3 |
| KLP42 | CN | NA | NA |
| 2 | 2 |
| KLP43 | CN | NA | NA |
| 3 | 3 |
| KLP50 | CN, LEV |
| 3 |
| 3 | 6 |
| KLP58A | CIP, LEV |
| 4 | NA | NA | 4 |
| KLP58B | CN, CIP, LEV |
| 4 |
| 4 | 8 |
| KLP63 | CN, AK, CIP, LEV |
| 3 |
| 4 | 7 |
| KLP65 | CN | NA | NA |
| 1 | 1 |
| KLP69 | CN, AK, CIP, LEV |
| 5 | — | — | 5 |
| KLP72 | CN, AK, CIP, LEV |
| 5 |
| 4 | 9 |
| KLP73 | CN | NA | NA |
| 1 | 1 |
| KLP78 | CN, CIP, LEV |
| 3 |
| 2 | 5 |
| KLP80 | CN, AK, CIP, LEV |
| 4 |
| 4 | 8 |
| KLP81 | CN, CIP |
| 3 |
| 3 | 6 |
| KLP88 | CN | NA | NA |
| 3 | 3 |
| KLP89 | CN, AK | NA | NA |
| 4 | 4 |
| KLP93 | CN | NA | NA |
| 4 | 4 |
| KLP96 | CN, AK, CIP, LEV |
| 7 |
| 5 | 12 |
| KLP99 | CN, AK, CIP, LEV |
| 4 |
| 2 | 6 |
| KLP100 | CN, AK, CIP, LEV |
| 4 |
| 2 | 6 |
| KLP101 | CN, CIP, LEV |
| 3 |
| 2 | 5 |
| KLP102 | CIP, LEV |
| 2 | NA | NA | 2 |
| KLP103 | CN, AK, CIP, LEV |
| 3 |
| 2 | 5 |
| KLP104 | CN, CIP, LEV |
| 3 |
| 2 | 5 |
| KLP107 | CN | NA | NA |
| 1 | 1 |
| KLP108 | CN, LEV |
| 3 |
| 2 | 5 |
| KLP110 | CN, CIP, LEV |
| 5 |
| 4 | 9 |
| KLP111 | CN | NA | NA |
| 3 | 3 |
| KLP112 | CN, CIP, LEV |
| 5 |
| 3 | 8 |
| KLP115 | CN, CIP, LEV |
| 5 |
| 1 | 6 |
| KLP117 | CIP, LEV |
| 5 | NA | NA | 5 |
| KLP119 | CN | NA | NA |
| 1 | 1 |
| KLP121 | CIP, LEV |
| 5 | NA | NA | 5 |
| KLP125 | CN, AK, CIP, LEV |
| 5 |
| 1 | 6 |
| KLP127 | CN, AK, CIP, LEV |
| 6 |
| 2 | 8 |
| KLP128 | CN | NA | NA | — | — | — |
| KLP129 | CN, AK, CIP, LEV |
| 5 |
| 4 | 9 |
| KLP134 | CN, AK, CIP, LEV |
| 5 |
| 4 | 9 |
| KLP136 | CIP, LEV |
| 2 |
| 1 | 3 |
| KLP137 | CIP, LEV |
| 3 | NA | NA | 3 |
| KLP140 | CN | NA | NA |
| 1 | 1 |
| KLP141 | CN | NA | NA |
| 1 | 1 |
| KLP144 | CN, AK, CIP, LEV |
| 1 |
| 3 | 4 |
| KLP147 | CN, LEV |
| 5 |
| 2 | 7 |
| KLP148 | CN | NA | NA | — | — | — |
| KLP154 | CIP |
| 4 | NA | NA | 4 |
| KLP157 | CN | NA | NA |
| 3 | 3 |
| KLP169 | CN, AK, CIP, LEV |
| 3 |
| 4 | 7 |
| KLP170 | CN, AK, CIP, LEV |
| 4 |
| 3 | 7 |
| KLP177 | CN, CIP, LEV | — | — | — | — | — |
| KLP180 | CN, AK, CIP, LEV |
| 6 |
| 2 | 8 |
| KLP184 | CIP, LEV |
| 3 | NA | NA | 3 |
| KLP186 | CN, CIP |
| 4 |
| 1 | 5 |
| KLP187 | CIP |
| 2 | NA | NA | 2 |
| KLP197 | CN, AK, CIP, LEV |
| 4 |
| 4 | 8 |
| KLP198 | CN, AK, CIP, LEV |
| 5 |
| 2 | 7 |
| KLP199 | CN | NA | NA |
| 2 | 2 |
| KLP201 | CN, CIP, LEV |
| 3 |
| 5 | 8 |
| KLP207 | CN, AK, CIP, LEV |
| 5 |
| 3 | 8 |
KL: Klebsiella pneumoniae, CN: gentamicin, AK: amikacin, CIP: ciprofloxacin, LEV: levofloxacin, and NA: not applicable.
Figure 4Representative PCR products of detected quinolone resistance genes. Lanes: (1) qnrB; (2) qnrC; (3) qnrD; (4) qnrS; (L) 100 bp ladder; (5) acc(6′)-Ib-cr; (6) oqxA; (7) oqxb; (8) qebA.